NSRX Ipo

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Published August 13, 2025 at 11:30 AM

TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses and excluding any exercise of the underwriters’ option to purchase any additional securities as described herein. In addition, Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions, to cover the over-allotment, if any.

Related Questions

What is the expected market capitalization of Nasus Pharma at the $8.00 IPO price and how does it compare to its current valuation? How will the $10 million gross proceeds impact the company's cash runway and planned R&D activities? What is the anticipated demand for the 1,250,000 shares and is the offering expected to be oversubscribed? How does Nasus Pharma’s IPO pricing and size compare to recent biotech and intranasal‑therapy IPOs? What are the lock‑up periods for insiders and existing shareholders, and when can the market expect secondary sales? What are the potential short‑term price movements post‑IPO given typical biotech IPO volatility? Who are the lead underwriters and what is their track record with similar pharmaceutical offerings? What are the key regulatory milestones for Nasus Pharma’s pipeline and how might they influence the stock’s risk profile? Are there any contingent or convertible securities (e.g., warrants, options) that could further dilute existing shareholders after the IPO? Will the underwriters’ over‑allotment option likely be exercised, and what effect could that have on the total float?